IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VERNIERI, CLAUDIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.310
AS - Asia 5.722
NA - Nord America 5.239
SA - Sud America 622
AF - Africa 164
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 2
Totale 18.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.009
DE - Germania 2.426
CN - Cina 1.777
SG - Singapore 1.641
IT - Italia 1.178
HK - Hong Kong 644
VN - Vietnam 529
GB - Regno Unito 502
BR - Brasile 481
RU - Federazione Russa 427
NL - Olanda 304
SE - Svezia 300
FR - Francia 299
IN - India 280
BD - Bangladesh 239
LT - Lituania 202
FI - Finlandia 185
CA - Canada 134
JP - Giappone 109
ID - Indonesia 102
IE - Irlanda 89
TR - Turchia 73
CI - Costa d'Avorio 71
ES - Italia 66
KR - Corea 65
PL - Polonia 54
AR - Argentina 51
DK - Danimarca 51
UA - Ucraina 42
MX - Messico 41
AU - Australia 37
CH - Svizzera 30
PH - Filippine 29
AT - Austria 28
IQ - Iraq 27
ZA - Sudafrica 27
BE - Belgio 26
TW - Taiwan 26
RO - Romania 21
UZ - Uzbekistan 21
EC - Ecuador 20
SA - Arabia Saudita 20
EG - Egitto 19
CL - Cile 16
JM - Giamaica 16
CO - Colombia 15
IL - Israele 15
IR - Iran 15
TH - Thailandia 15
PK - Pakistan 14
NP - Nepal 13
MY - Malesia 12
PT - Portogallo 12
NO - Norvegia 11
PE - Perù 11
PY - Paraguay 10
GR - Grecia 9
TT - Trinidad e Tobago 9
AE - Emirati Arabi Uniti 8
MA - Marocco 8
TN - Tunisia 8
VE - Venezuela 8
JO - Giordania 7
KE - Kenya 7
LV - Lettonia 7
UY - Uruguay 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
KG - Kirghizistan 6
AZ - Azerbaigian 5
BB - Barbados 5
HU - Ungheria 5
KZ - Kazakistan 5
LB - Libano 5
OM - Oman 5
BY - Bielorussia 4
IS - Islanda 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
DO - Repubblica Dominicana 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
MD - Moldavia 3
NG - Nigeria 3
NI - Nicaragua 3
RS - Serbia 3
AG - Antigua e Barbuda 2
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
BO - Bolivia 2
CY - Cipro 2
ET - Etiopia 2
LY - Libia 2
MU - Mauritius 2
SC - Seychelles 2
TZ - Tanzania 2
Totale 18.077
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.124
Singapore 830
Ashburn 771
Dallas 664
Hong Kong 522
San Jose 395
Milan 322
Southend 322
Hefei 317
Chandler 254
Beijing 225
Council Bluffs 193
Ho Chi Minh City 173
Los Angeles 173
Fairfield 156
New York 125
Helsinki 119
Hanoi 118
Bengaluru 116
Vilnius 109
Lauterbourg 101
Santa Clara 93
Moscow 91
Wilmington 91
Seattle 89
Houston 88
Guangzhou 85
Dublin 80
Buffalo 77
Abidjan 71
Princeton 66
Woodbridge 66
Jakarta 64
Munich 64
Tokyo 64
Amsterdam 62
Ann Arbor 60
Cambridge 59
Rome 58
Shanghai 58
Chicago 50
São Paulo 50
Dearborn 49
Nanjing 47
Cangzhou 45
Toronto 41
Da Nang 40
Seoul 40
Naples 39
Nuremberg 38
Tianjin 38
Hanover 34
Jinan 33
Lappeenranta 33
Istanbul 32
London 30
Kaunas 29
Phoenix 29
Berlin 28
Columbus 28
Des Moines 27
Shenyang 27
Boardman 26
Klaipėda 26
Shenzhen 26
St Petersburg 26
Turku 26
Redwood City 25
Hangzhou 24
Montreal 24
Orem 24
Paris 24
Washington 24
Rho 23
The Dalles 23
Atlanta 22
Warsaw 21
Brussels 20
Changsha 19
Hyderabad 19
Brooklyn 18
Chennai 18
Elk Grove Village 18
Madrid 18
Silver Spring 18
Chengdu 17
Düsseldorf 17
Fuzhou 17
Genoa 17
Nanchang 17
Stockholm 17
Bologna 16
Salt Lake City 16
San Diego 16
Turin 16
Zhengzhou 16
Biên Hòa 15
Central District 15
Manchester 15
Tashkent 15
Totale 11.076
Salva come PNG Salva come JPEG
Nome #
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial 1.003
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 514
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 349
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison 319
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State 317
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab 316
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers 315
Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) 299
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC 295
Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction 294
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer 286
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 280
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma : the FAME Trial 275
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer 273
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles 269
THE INTERPLAY BETWEEN CDK1/CLBS AND PP2A/CDC55 IN ADAPTATION TO THE SPINDLE ASSEMBLY CHECKPOINT (SAC) 255
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 248
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up 247
Targeting cancer metabolism : Dietary and pharmacologic interventions 246
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. 244
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies 238
Combination of baseline LDH, performance status and age as integrated algorithm to identify solid tumor patients with higher probability of response to anti PD-1 and PD-l1 monoclonal antibodies 236
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study 233
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives 231
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence 226
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape 219
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 217
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 217
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 216
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 212
Metformin plus /- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma : The FAME trial 208
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders 207
Impact of diabetes and metformin use on enteropancreatic neuroendocrine tumors : Post hoc analysis of the CLARINET study 206
Update on medical treatment of small intestinal neuroendocrine tumors 199
Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis 198
Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer 194
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes 193
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) 192
Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process 192
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting 191
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 190
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 190
Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia 187
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 186
Fasting-mimicking diet and hormone therapy induce breast cancer regression 186
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 184
Diet and supplements in cancer prevention and treatment : clinical evidences and future perspectives 179
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 178
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study 178
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 177
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer 175
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal 174
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 171
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 163
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 160
Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer 149
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2 148
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology 147
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 143
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 143
The impact of COVID-19 on diagnosis of recurrent breast cancer 141
International consensus on fasting terminology 135
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status 135
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer 133
Central Obesity, Body Mass Index, Metabolic Syndrome and Mortality in Mediterranean Breast Cancer Patients 133
Cellular response upon proliferation in the presence of an active mitotic checkpoint 128
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors 123
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology 121
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 121
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care 117
Management of patients with locally recurrent rectal cancer with a previous history of distant metastases: retrospective cohort study 113
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis 111
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities 111
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer 106
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world 105
Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters 105
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer 103
HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness 103
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications 103
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 102
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis 101
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment 95
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 94
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications 94
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 93
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial 90
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 89
Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection 86
The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence 84
Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure 81
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program 77
Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55 77
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential 75
Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence 75
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 73
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer 72
Fasting-mimicking diet plus chemotherapy in breast cancer treatment 70
DHA affects microtubule dynamics through reduction of phospho-TCTP levels and enhances the antiproliferative effect of T-DM1 in trastuzumab-resistant HER2-positive breast cancer cell lines 65
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients 65
Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer 65
Totale 18.247
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.440
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.440
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 0 0 0 0 0 0 0 43 73
2021/2022822 54 63 62 47 45 51 68 67 92 85 46 142
2022/2023816 96 119 70 63 79 153 32 60 68 14 45 17
2023/20241.988 43 43 43 42 136 78 329 261 136 260 305 312
2024/20254.350 279 307 262 340 258 179 241 428 284 527 400 845
2025/20269.051 1.011 916 1.297 765 607 432 1.144 411 874 762 832 0
Totale 18.648